IN SILICO HEAD-TO-HEAD COMPARISON OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC IN TYPE 1 DIABETES

被引：0

作者：

Visentin, R. ^{[1
]}

Schiavon, M. ^{[1
]}

Giegerich, C. ^{[2
]}

Sieber, J. ^{[2
]}

Man, C. Dalla ^{[1
]}

Cobelli, C. ^{[1
]}

Klabunde, T. ^{[2
]}

机构：

[1] Univ Padua, Dept Informat Engn, Padua, Italy

[2] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

037

引用

页码：A18 / A18

页数：1

共 50 条

[1] In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
Schiavon, Michele
Visentin, Roberto
Giegerich, Clemens
Sieber, Jochen
Dalla Man, Chiara
Cobelli, Claudio
Klabunde, Thomas
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) : 553 - 561
[2] A PK/PD and Metabolic Head-to-Head Comparison of Clinical Doses of Insulin Glargine U300 and Degludec in Type 1 Diabetes
Lucidi, Paola
Porcellati, Francesca
Candeloro, Paola
Cioli, Patrizia
Pascucci, Chiara
Bolli, Geremia B.
Fanelli, Carmine
[J]. DIABETES, 2019, 68
[3] Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units . mL-1 and Insulin Degludec 100 units . mL-1 in Type 1 Diabetes
Lucidi, Paola
Candeloro, Paola
Cioli, Patrizia
Marinelli Andreoli, Anna
Pascucci, Chiara
Gambelunghe, Angela
Bolli, Geremia B.
Fanelli, Carmine G.
Porcellati, Francesca
[J]. DIABETES CARE, 2021, 44 (01) : 125 - 132
[4] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Philis-Tsimikas, Athena
Klonoff, David C.
Khunti, Kamlesh
Bajaj, Harpreet S.
Leiter, Lawrence A.
Hansen, Melissa, V
Troelsen, Lone N.
Ladelund, Steen
Heller, Simon
Pieber, Thomas R.
[J]. DIABETOLOGIA, 2020, 63 (04) : 698 - 710
[5] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Athena Philis-Tsimikas
David C. Klonoff
Kamlesh Khunti
Harpreet S. Bajaj
Lawrence A. Leiter
Melissa V. Hansen
Lone N. Troelsen
Steen Ladelund
Simon Heller
Thomas R. Pieber
[J]. Diabetologia, 2020, 63 : 698 - 710
[6] More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
Rosenstock, Julio
Cheng, Alice
Ritzel, Robert
Bosnyak, Zsolt
Devisme, Christine
Cali, Anna M. G.
Sieber, Jochen
Stella, Peter
Wang, Xiangling
Frias, Juan P.
Roussel, Ronan
Bolli, Geremia B.
[J]. DIABETES CARE, 2018, 41 (10) : 2147 - 2154
[7] Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats
Gilor, C.
Culp, W.
Ghandi, S.
do Carmo Emidio e Silva, J. A.
Ladhar, A.
Hulsebosch, S.
[J]. DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 69 : 19 - 29
[8] EFFICACY AND SAFETY OF INSULIN GLARGINE-300 U/ML VS INSULIN DEGLUDEC-100 U/ML IN INSULIN-NAIVE ADULTS WITH T2DM: FIRST HEAD-TO-HEAD RANDOMISED CLINICAL TRIAL
Cheng, A.
Rosenstock, J.
Ritzel, R.
Bosnyak, Z.
Devisme, C.
Wang, X.
Sieber, J.
Roussel, R.
Bolli, G. B.
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A30
[9] Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial
Battelino, Tadej
Danne, Thomas
Edelman, Steve, V
Choudhary, Pratik
Renard, Eric
Westerbacka, Jukka
Mukherjee, Bhaswati
Pilorget, Valerie
Coudert, Mathieu
Bergenstal, Richard M.
[J]. DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 545 - 555
[10] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SERBIA
Mihajlovic, J.
Bogdanovic, M.
Foumier, M.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A481 - A481

← 1 2 3 4 5 →